Status:
COMPLETED
Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis
Lead Sponsor:
Nantes University Hospital
Conditions:
Relapsing-remitting Multiple Sclerosis
Eligibility:
All Genders
Brief Summary
The aim of this observational study is to compare Dimethyl fumarate (DMF) and Teriflunomide on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from French...
Eligibility Criteria
Inclusion
- RRMS Patients with an EDSS score ranging between 0 and 5.5, who initiated either DMF or Teriflunomide before 1/01/2016 and with an available MRI scan and EDSS assessment respectively within 12 and 6 months before treatment initiation Patients who had consent to OFSEP registry Naive patient or treated with prior first line treatment : interferon, glatiramer acetate
Exclusion
- Patient with progressive multiple sclerosis
- Patients with prior second line Patient with no MRI or EDSS score within the year before DMF or Teriflunomide initiation.
Key Trial Info
Start Date :
May 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2017
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT03302442
Start Date
May 1 2017
End Date
October 1 2017
Last Update
October 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nantes University Hospital
Nantes, France, 44093